Join
Login
Join
Login
"Where Everyone Has an MBA"
Tel: (612) 246-4616
Home
Financial Analysis
Companies
Industries
Glossary
About
Frequently Asked Questions
User Testimonials
Contact Us
Navigation
Home
Financial Analysis
Companies
Industries
Glossary
About
- Frequently Asked Questions
- User Testimonials
Contact Us
Karyopharm Therapeutics Inc - SIC # 8731 - COMMERCIAL PHY_SICAL AND BIOLOGICAL RESEARCH
Ticker
Exchange
SIC #
Website
Latest Ticker
KPTI
Nasdaq
8731
https://karyopharm.com/
Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:
Latest Headlines for Karyopharm Therapeutics Inc
Karyopharm Announces Presentations in Endometrial Cancer and Myelofibrosis at the 2024 American Society of Clinical Oncology Annual Meeting
- Apr 24th, 2024 8:01 pm
Karyopharm Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
- Apr 1st, 2024 8:05 pm
Karyopharm to Participate at Barclays 26th Annual Global Healthcare and Leerink Partners Global Biopharma Conferences
- Mar 6th, 2024 9:05 pm
Insider Sell: President and CEO Richard Paulson Sells 99,844 Shares of Karyopharm Therapeutics ...
- Mar 5th, 2024 4:53 am
Karyopharm Therapeutics Inc. (NASDAQ:KPTI) Q4 2023 Earnings Call Transcript
- Mar 1st, 2024 2:21 pm
Q4 2023 Karyopharm Therapeutics Inc Earnings Call
- Mar 1st, 2024 3:03 am
Karyopharm Therapeutics (KPTI) Q4 2023 Earnings Call Transcript
- Feb 29th, 2024 11:15 pm
Karyopharm Therapeutics (KPTI) Reports Q4 Loss, Tops Revenue Estimates
- Feb 29th, 2024 1:40 pm
Karyopharm Reports Fourth Quarter and Full Year 2023 Financial Results and Highlights Recent Company Progress
- Feb 29th, 2024 12:30 pm
7 Biotech Penny Stocks on the Verge of Clinical Trial Victory
- Feb 25th, 2024 6:37 pm
Karyopharm to Report Fourth Quarter and Full Year 2023 Financial Results on February 29, 2024
- Feb 22nd, 2024 12:00 pm
Xencor (XNCR) Surges 13.4%: Is This an Indication of Further Gains?
- Feb 19th, 2024 8:37 am
Ardelyx (ARDX) Expected to Beat Earnings Estimates: Can the Stock Move Higher?
- Feb 15th, 2024 3:00 pm
Will Karyopharm Therapeutics (KPTI) Report Negative Q4 Earnings? What You Should Know
- Feb 14th, 2024 3:00 pm
Karyopharm Therapeutics (NASDAQ:KPTI) adds US$104m to market cap in the past 7 days, though investors from three years ago are still down 90%
- Feb 7th, 2024 11:33 am
Karyopharm Announces Preliminary Unaudited 2023 Revenue and 2024 Objectives
- Jan 8th, 2024 1:30 pm
Karyopharm to Present at 42nd Annual J.P. Morgan Healthcare Conference
- Jan 3rd, 2024 12:00 pm
Karyopharm Shares Data at ASH 2023 Showing Strong SVR and TSS Durability Observed from Phase 1 Study of Selinexor 60mg and Ruxolitinib in JAK Inhibitor (JAKi)-Naïve Myelofibrosis Patients, with no SVR or TSS Progressions Observed As of the Data Cutoff(1)
- Dec 11th, 2023 1:15 am
Great week for Karyopharm Therapeutics Inc. (NASDAQ:KPTI) institutional investors after losing 84% over the previous year
- Dec 6th, 2023 10:52 am
Karyopharm to Participate at Upcoming Investor Conferences
- Nov 8th, 2023 9:05 pm
Scroll